首页> 美国卫生研究院文献>Diabetology Metabolic Syndrome >Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

【2h】

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

机译：SGLT2抑制剂Luseogliflozin的治疗可改善啮齿类糖尿病小鼠的非酒精性脂肪性肝炎

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundInsulin resistance with elevated glucose is a risk factor for non-alcoholic steatohepatitis (NASH). We investigated the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor luseogliflozin on NASH development using a rodent model.

机译：背景技术血糖升高引起的胰岛素抵抗是非酒精性脂肪性肝炎（NASH）的危险因素。我们使用啮齿动物模型调查了钠葡萄糖共转运蛋白2（SGLT2）抑制剂luseogliflozin对NASH发育的影响。

著录项

期刊名称 Diabetology Metabolic Syndrome
作者
Shirong Qiang; Yusuke Nakatsu; Yasuyuki Seno; Midori Fujishiro; Hideyuki Sakoda; Akifumi Kushiyama; Keiichi Mori; Yasuka Matsunaga; Takeshi Yamamotoya; Hideaki Kamata; Tomoichiro Asano;
展开▼
作者单位

展开▼
年(卷),期 2015(7),-1
年度 2015
页码 104
总页数 7
原文格式 PDF
正文语种
中图分类基础医学;
关键词
Diabetes mellitus Nonalcoholic steatohepatitis SGLT2 inhibitor Luseogliflozin;

机译：糖尿病;非酒精性脂肪性肝炎;SGLT2抑制剂;路格列净;

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of the SGLT2 Inhibitor Luseogliflozin in Japanese Patients With Type 2 Diabetes Mellitus Stratified According to Baseline Body Mass Index: Pooled Analysis of Data From 52-Week Phase III Trials [J] . Sakai Soichi, Kaku Kohei, Seino Yutaka, Clinical therapeutics . 2016,第4期

机译：根据基线体重指数分层的日本2型糖尿病患者中SGLT2抑制剂Luseogliflozin的疗效和安全性：52周III期试验数据的汇总分析
2. Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus [J] . Jinnouchi Hideaki, Nozaki Kazunari, Watase Hirotaka, Advances in therapy. . 2016,第3期

机译：肾脏功能下降对持续性血糖监测对日本2型糖尿病患者评估的选择性SGLT2抑制剂Luseogliflozin降糖作用的影响
3. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology [J] . Norio Akuta, Yusuke Kawamura, Shunichiro Fujiyama, Internal medicine. . 2020,第16期

机译：非酒精性脂肪肝病的SGLT2抑制剂治疗结果复杂于糖尿病：对临床特征和肝脏组织病理学的长期影响
4. Lipidomics of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in a Mouse Model via LC-HRMS [C] . Rainey E. Patterson, Srilaxmi Kalavalapalli, Nishanth E. Sunny, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：通过LC-HRMS在小鼠模型中非酒精性脂肪肝疾病和非酒精脂肪肝炎的脂质组
5. Potential of Carbon Monoxide Releasing Molecule-A1 Against Hepatotoxicity and in Improving Nonalcoholic Steatohepatitis [D] . ?Upadhyay, Kapil Kumar 2019

机译：一氧化碳的潜力释放分子 -A1 针对肝毒性和提高酒精性脂肪性肝炎
6. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model [O] . Atsuo Tahara, Toshiyuki Takasu 2019

机译：SGLT2抑制剂依普列净单独或与吡格列酮联用可预防2型糖尿病啮齿动物模型中非酒精性脂肪性肝炎的进展
7. Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus [O] . Shirong Qiang, Yusuke Nakatsu, Yasuyuki Seno, 2015

机译：SGLT2抑制剂Luseogliflozin的治疗可改善啮齿类糖尿病小鼠的非酒精性脂肪性肝炎

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

摘要

著录项

相似文献

相关主题

期刊订阅